{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:00:10Z","timestamp":1790650810170,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03579-3","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:11:30Z","timestamp":1776258690000},"page":"2736-2751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Foslevodopa\/Foscarbidopa Subcutaneous Infusion Safety and Efficacy in Patients with and Without Prior Deep Brain Stimulation"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03781167","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tove","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Mart\u00ednez-Castrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H. B.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dhanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Aldred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Resmi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavnit","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S. C.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"1","key":"3579_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Azulay JP, Odin P, et al. Economic burden of Parkinson\u2019s disease: a multinational, real-world, cost-of-illness study. Drugs Real World Outcomes. 2024;11(1):1\u201311. https:\/\/doi.org\/10.1007\/s40801-023-00410-1.","journal-title":"Drugs Real World Outcomes"},{"issue":"0","key":"3579_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/ndt.s273121","volume":"19","author":"N Masood","year":"2023","unstructured":"Masood N, Jimenez-Shahed J. Effective management of \u201cOFF\u201d episodes in Parkinson\u2019s disease: emerging treatment strategies and unmet clinical needs. Neuropsychiatr Dis Treat. 2023;19(0):247\u201366. https:\/\/doi.org\/10.2147\/ndt.s273121.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"3579_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/11310940-000000000-00000","volume":"24","author":"A Antonini","year":"2010","unstructured":"Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson\u2019s disease. CNS Drugs. 2010;24(2):119\u201329. https:\/\/doi.org\/10.2165\/11310940-000000000-00000.","journal-title":"CNS Drugs"},{"key":"3579_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2017.03.001","author":"J Timpka","year":"2017","unstructured":"Timpka J, Nitu B, Datieva V, Odin P, Antonini A. Device-aided treatment strategies in advanced Parkinson\u2019s disease. Int Rev Neurobiol. 2017. https:\/\/doi.org\/10.1016\/bs.irn.2017.03.001.","journal-title":"Int Rev Neurobiol"},{"issue":"3","key":"3579_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/01945998221120189","volume":"168","author":"R Baudouin","year":"2023","unstructured":"Baudouin R, Lechien JR, Carpentier L, Gurruchaga J, Lisan Q, Hans S. Deep brain stimulation impact on voice and speech quality in Parkinson\u2019s disease: a systematic review. Otolaryngol Head Neck Surg. 2023;168(3):307\u201318. https:\/\/doi.org\/10.1177\/01945998221120189.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"3579_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin P, Foltynie T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol. 2019;15(4):234\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0145-9.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"3579_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s13760-022-01874-8","volume":"122","author":"AM de Noordhout","year":"2022","unstructured":"de Noordhout AM, Mouchamps M, Remacle JM, Delstanche S, Bonhomme V, Gonce M. Subthalamic deep brain stimulation versus best medical treatment: a 12-year follow-up. Acta Neurol Belg. 2022;122(1):197\u2013202. https:\/\/doi.org\/10.1007\/s13760-022-01874-8.","journal-title":"Acta Neurol Belg"},{"key":"3579_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221108018","volume":"15","author":"D Nyholm","year":"2022","unstructured":"Nyholm D, Jost WH. Levodopa\u2013entacapone\u2013carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance. Ther Adv Neurol Disord. 2022;15:17562864221108018. https:\/\/doi.org\/10.1177\/17562864221108018.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"3579_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mdc3.13228","volume":"8","author":"I Boura","year":"2021","unstructured":"Boura I, Haliasos N, Giannopoulou \u0399, Karabetsos D, Spanaki C. Combining device-aided therapies in Parkinson\u2019s disease: a case series and a literature review. Mov Disord Clin Pract. 2021;8(5):750\u20137. https:\/\/doi.org\/10.1002\/mdc3.13228.","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"3579_CR10","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/s1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase\u00a03 trial. Lancet Neurol. 2022;21(12):1099\u2013109. https:\/\/doi.org\/10.1016\/s1474-4422(22)00400-8.","journal-title":"Lancet Neurol"},{"issue":"6","key":"3579_CR11","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase\u00a03 study. Neurol Ther. 2023;12(6):1937\u201358. https:\/\/doi.org\/10.1007\/s40120-023-00533-1.","journal-title":"Neurol Ther"},{"issue":"1","key":"3579_CR12","doi-asserted-by":"publisher","first-page":"970534","DOI":"10.1155\/2015\/970534","volume":"2015","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, et al. Minimal clinically important difference on Parkinson\u2019s Disease Sleep Scale 2nd version. Parks Dis. 2015;2015(1):970534. https:\/\/doi.org\/10.1155\/2015\/970534.","journal-title":"Parks Dis"},{"issue":"1\u20132","key":"3579_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000455863","volume":"48","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, et al. Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant? Neuroepidemiology. 2017;48(1\u20132):1\u20138. https:\/\/doi.org\/10.1159\/000455863.","journal-title":"Neuroepidemiology"},{"issue":"5","key":"3579_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society\u2013sponsored unified Parkinson\u2019s disease rating scale. Mov Disord. 2017;32(5):789\u201393. https:\/\/doi.org\/10.1002\/mds.26960.","journal-title":"Mov Disord"},{"issue":"12","key":"3579_CR15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","volume":"21","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, et al. Minimal clinically important difference on the motor examination part of MDS-UPDRS. Park Relat Disord. 2015;21(12):1421\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.10.006.","journal-title":"Park Relat Disord"},{"issue":"Suppl 19","key":"3579_CR16","doi-asserted-by":"publisher","first-page":"S545","DOI":"10.4103\/2152-7806.187532","volume":"7","author":"SM Farris","year":"2016","unstructured":"Farris SM, Giroux ML. Rapid assessment of gait and speech after subthalamic deep brain stimulation. Surg Neurol Int. 2016;7(Suppl 19):S545\u201350. https:\/\/doi.org\/10.4103\/2152-7806.187532.","journal-title":"Surg Neurol Int"},{"key":"3579_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2022.806513","volume":"16","author":"NG Pozzi","year":"2022","unstructured":"Pozzi NG, Palmisano C, Reich MM, et al. Troubleshooting gait disturbances in Parkinson\u2019s disease with deep brain stimulation. Front Hum Neurosci. 2022;16:806513. https:\/\/doi.org\/10.3389\/fnhum.2022.806513.","journal-title":"Front Hum Neurosci"},{"issue":"7","key":"3579_CR18","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/mds.21482","volume":"22","author":"P Piboolnurak","year":"2007","unstructured":"Piboolnurak P, Lang AE, Lozano AM, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson\u2019s disease. Mov Disord. 2007;22(7):990\u20137. https:\/\/doi.org\/10.1002\/mds.21482.","journal-title":"Mov Disord"},{"issue":"1","key":"3579_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52177","volume":"7","author":"ST Jost","year":"2024","unstructured":"Jost ST, Aloui S, Evans J, et al. Neurostimulation for advanced Parkinson disease and quality of life at 5\u00a0years. JAMA Netw Open. 2024;7(1):e2352177. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52177.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3579_CR20","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00415-016-8077-4","volume":"263","author":"E Lezcano","year":"2016","unstructured":"Lezcano E, G\u00f3mez-Esteban JC, Tijero B, et al. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson\u2019s disease. J Neurol. 2016;263(5):895\u2013905. https:\/\/doi.org\/10.1007\/s00415-016-8077-4.","journal-title":"J Neurol"},{"issue":"3","key":"3579_CR21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mds.28382","volume":"36","author":"M Picillo","year":"2021","unstructured":"Picillo M, Phokaewvarangkul O, Poon Y, et al. Levodopa versus dopamine agonist after subthalamic stimulation in Parkinson\u2019s disease. Mov Disord. 2021;36(3):672\u201380. https:\/\/doi.org\/10.1002\/mds.28382.","journal-title":"Mov Disord"},{"issue":"3","key":"3579_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/brainsci12030343","volume":"12","author":"D Georgiev","year":"2022","unstructured":"Georgiev D, Delali\u0107 S, Kri\u017enar NZ, Socher A, Gurevich T, Tro\u0161t M. Switching and combining device-aided therapies in advanced Parkinson\u2019s disease: a double centre retrospective study. Brain Sci. 2022;12(3):343. https:\/\/doi.org\/10.3390\/brainsci12030343.","journal-title":"Brain Sci"},{"issue":"21","key":"3579_CR23","doi-asserted-by":"publisher","first-page":"e2078","DOI":"10.1212\/wnl.0000000000207858","volume":"101","author":"D P\u00fcrner","year":"2023","unstructured":"P\u00fcrner D, Hormozi M, Wei\u00df D, et al. Nationwide retrospective analysis of combinations of advanced therapies in patients with Parkinson disease. Neurology. 2023;101(21):e2078\u201393. https:\/\/doi.org\/10.1212\/wnl.0000000000207858.","journal-title":"Neurology"},{"key":"3579_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.96.15_supplement.2347","author":"J Aldred","year":"2021","unstructured":"Aldred J, Amjad F, Johnson A, et al. A retrospective study evaluating the use of anti-Parkinsonian medications in patients with advanced Parkinson\u2019s disease who are treated with levodopa-carbidopa intestinal gel and deep brain stimulation: The PD-DUAL Study (2347). Neurology. 2021. https:\/\/doi.org\/10.1212\/wnl.96.15_supplement.2347.","journal-title":"Neurology"},{"issue":"8","key":"3579_CR25","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mdc3.13338","volume":"8","author":"G Fern\u00e1ndez-Pajar\u00edn","year":"2021","unstructured":"Fern\u00e1ndez-Pajar\u00edn G, Sesar \u00c1, Ares B, et al. Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients. Mov Disord Clin Pract. 2021;8(8):1216\u201324. https:\/\/doi.org\/10.1002\/mdc3.13338.","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"3579_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38555-2","volume":"13","author":"A Gessani","year":"2023","unstructured":"Gessani A, Cavallieri F, Fioravanti V, et al. Long-term effects of subthalamic nucleus deep brain stimulation on speech in Parkinson\u2019s disease. Sci Rep. 2023;13(1):11462. https:\/\/doi.org\/10.1038\/s41598-023-38555-2.","journal-title":"Sci Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03579-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03579-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03579-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:35Z","timestamp":1780116695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03579-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3579"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03579-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following commercial and other associations that may be considered to pose an actual or perceived competing interest related to the material submitted in the current paper have been disclosed\/declared by the authors: Tove Henriksen has served as a speaker for AbbVie Inc., Britannia, EVER Pharma, Nordic Infucare, Neuroderm, Lundbeck, Ipsen, and Convatec; is a primary investigator on the NCT04380142 and NCT03781167 clinical trials as well as on a study sponsored by Britannia; and is a board member of a data monitoring committee for a study sponsored by Lundbeck. Juan Carlos Mart\u00ednez-Castrillo has received honoraria as a speaker from AbbVie Inc., Allergan (now AbbVie Inc.), Bial, Krka, Merz, Ipsen, Italfarmaco, Lundbeck, Medtronic, TEVA, UCB, and Zambon; travel grants from AbbVie Inc., Allergan (now AbbVie Inc.), Bial, Italfarmaco, UCB, Merz, Krka, and Zambon; research grants from AbbVie Inc., Allergan (now AbbVie Inc.), Merz, Italfarmaco, Lundbeck, UCB, and Zambon; and participated in advisory boards for AbbVie Inc., Bial, Merz, Ipsen, Italfarmaco, Lundbeck, Orion, Stada, UCB, and Zambon. Mark H.B. Huisman has received honorarium for participation in advisory boards for AbbVie Inc. and Eurocept International; and is a principal investigator for the NCT04380142 and NCT03781167 clinical trials. Sara Dhanani received advisory honoraria from Amneal as well as AbbVie Inc., and is an investigator on studies funded by AbbVie Inc. Elizabeth Peckham receives funding for clinical trial research from the following companies: AbbVie Inc., Annovis, Amylyx, Aptinyx, Biogen, Biohaven, Bristol Meyers Squibb, Cerevance, Cerevel, Ferrer, Inhibikase, Lilly, Roche, Sun Pharma, Takeda, TruBinding, and Ventus Therapeutics in the past two years. Jason Aldred is a study investigator for AbbVie Inc., AC Immune, Annovis, Aptinyx, AstraZeneca, Atara, Athira, Biogen, Biovie, Boston Scientific, Celgene, Cerevance, Cerevel, Denali, EIP Pharma, Eli Lilly, Impax, Inhibikase, IRL Therapeutics, Merz, Neuraly, Neurocrine, Neuoderm, Novartis, PD Gene\/PSG, Praxis, Revance, Roche\/Genentech, Sage, Sanofi\/Genzyme, Scion Neurostem, Takeda, Theravance, Triplet\/HSG, and UCB Pharma; has received honorarium from Abbott, AbbVie Inc., Allergan (now AbbVie Inc.), Boston Scientific, Medtronic, Teva, and US WorldMeds. Lars Bergmann, Megha B. Shah, Resmi Gupta, Pavnit Kukreja, and Juan Carlos Parra are employees of AbbVie Inc., and may hold AbbVie Inc. stock and\/or stock options. Victor S.C. Fung receives a salary from NSW Health; has received unrestricted research grants from The Michael J. Fox Foundation; and receives royalties from Health Press, Taylor and Francis Group LLC, and Oxford University Press.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The independent ethics committees (IECs) or institutional review boards (IRBs) at each study site approved the clinical trial protocol, informed consent forms, and recruitment materials before patient enrollment (with the names of all IECs\/IRBs providing approval previously published in the Aldred et al. [\n                      \n                      ] Supplementary Appendix). The clinical trial was conducted in accordance with its protocol and the International Conference for Harmonization guidelines, applicable regulations, and the Declaration of Helsinki (and its later amendments). All patients provided written informed consent before initiating any study-specific procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}